Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019

(2021) Otávio M. Espíndola et al.   ANNALS OF NEUROLOGY

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

(2020) Shengyu Zhang et al.   CLINICAL DRUG INVESTIGATION

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

(2020) Corrado Campochiaro et al.   European Journal of Internal Medicine

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

(2020) Chi Zhang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

(2020) Tobias Herold et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

(2020) Luca Quartuccio et al.   JOURNAL OF CLINICAL VIROLOGY

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

(2020) T. Klopfenstein et al.   MEDECINE ET MALADIES INFECTIEUSES

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytokine release syndrome in severe COVID-19

(2020) John B. Moore et al.   SCIENCE

SARS-CoV-2 and COVID-19: The most important research questions

(2020) Kit-San Yuen et al.   Cell and Bioscience

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

(2020) Emanuel Della-Torre et al.   ANNALS OF THE RHEUMATIC DISEASES

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

(2020) Dennis McGonagle et al.   AUTOIMMUNITY REVIEWS

Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients

(2020) Timothée Klopfenstein et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients

(2020) Lorenzo M. Canziani et al.   JOURNAL OF AUTOIMMUNITY

Use of the IL‐6R Antagonist Tocilizumab in Hospitalized COVID‐19 Patients

(2020) Krish Patel et al.   JOURNAL OF INTERNAL MEDICINE

Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID‐19: a retrospective cohort study.

(2020) Johannes Eimer et al.   JOURNAL OF INTERNAL MEDICINE

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study

(2020) G Rojas-Marte et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

(2020) Tomás Palanques-Pastor et al.   European Journal of Hospital Pharmacy-Science and Practice

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

(2020) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE